Tech Company Financing Transactions

SciTech Development Funding Round

SciTech Development closed a $3.2 million funding round on 6/4/2024. Investors included Pointe Angels, Storm Lake Capital and private investors.

Transaction Overview

Announced On
6/4/2024
Transaction Type
Venture Equity
Amount
$3,200,000
Round
Undisclosed
Investors

Pointe Angels (Lead Investor)

Storm Lake Capital (Lead Investor)

Proceeds Purpose
The company intends to use the funds to advance its Phase 1b clinical trials of ST-001 for T-NHL and subsequent clinical trials for small cell lung cancer.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2401 W. Belvedere Ave
Baltimore, MD 21215
USA
Phone
Undisclosed
Email Address
Overview
SciTech Development LLC was formed as a spin-off from the Karmanos Cancer Institute (KCI) and Wayne State University (WSU). As a recipient of a U.S. Small Business Innovation Research (SBIR) grant, SciTech's research focused on oncology drugs, specifically on fenretinide. Fenretinide had shown great promise as a cancer drug. However, fenretinide does not easily dissolve in the body, so it cannot get to cancer cells in high enough doses, which severely limited its effectiveness. The National Cancer Institute (NCI) issued a challenge to find a way to deliver fenretinide to cancer cells in greater concentrations, but without adverse or toxic side effects. SciTech subsequently received an SBIR grant from the NCI and successfully delivered on the promise of fenretinide. We developed and patented our first drug candidate ST-001 nanoFenretinide and proprietary SciTech Drug Delivery Platform (SDP).
Profile
SciTech Development LinkedIn Company Profile
Social Media
SciTech Development Company Twitter Account
Company News
SciTech Development News
Facebook
SciTech Development on Facebook
YouTube
SciTech Development on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Earle Holsapple
  Earle  Holsapple LinkedIn Profile  Earle  Holsapple Twitter Account  Earle  Holsapple News  Earle  Holsapple on Facebook
Chief Financial Officer
Andrew Stumpf
  Andrew Stumpf LinkedIn Profile  Andrew Stumpf Twitter Account  Andrew Stumpf News  Andrew Stumpf on Facebook
Chief Operating Officer
Louis Scarmoutzos
  Louis Scarmoutzos LinkedIn Profile  Louis Scarmoutzos Twitter Account  Louis Scarmoutzos News  Louis Scarmoutzos on Facebook
Chief Scientific Officer
Ralph Parchment
  Ralph Parchment LinkedIn Profile  Ralph Parchment Twitter Account  Ralph Parchment News  Ralph Parchment on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/4/2024: Mitiga venture capital transaction
Next: 6/4/2024: Vilya venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary